Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

ASH 2019 | MGTA-145 with plerixafor induces rapid mobilization of CD34+ HSCs

John DiPersio • 30 Nov 2019

ASH 2019

General MGTA-145 Plerixafor

Granulocyte colony-stimulating factor (G-CSF) is the standard of care for mobilization of hematopoietic stem cells (HSCs). MGTA-145 (GroβT), a CXCR2 agonist, in combination with plerixafor, a CXCR4 inhibitor, has the potential to rapidly and reliably mobilize robust numbers of HSCs with a single dose and same-day apheresis for transplant that is free from G-CSF. John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, discusses a Phase I dose-escalating study to evaluate the safety, pharmacokinetics and pharmacodynamics of MGTA-145 as a single agent and in combination with plerixafor. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Identifying the optimal toxic payloads for antibody-based SCT conditioning using SAv-drug conjugates

John DiPersio • 21 Feb 2023

LBA: CD33 CRISPR/Cas9 gene-edited donor allograft in patients with AML at risk of relapse post-HSCT

John DiPersio • 21 Feb 2023

ALL highlights: tisa-cel reinfusion in B-ALL & targeting CD5 and CD7 with CAR-Ts in T-ALL

John DiPersio • 21 Feb 2023

Advantages & concerns associated with the use of ADC-based conditioning in SCT recipients

John DiPersio • 21 Feb 2023

Related Videos

The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024

Natacha Bolaños • 16 Apr 2024

Distinguishing late-onset neutropenia from classical primary neutropenia

Carlo Dufour • 15 Apr 2024

The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract

James Ferrara • 16 Apr 2024

The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives

Claire Horgan • 15 Apr 2024